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treatment for cutaneous T-cell lymphoma (CTCL).1,2
The first description of total skin electron therapy came
from Stanford University.1,3 Prolonged treatment to
≥3000 cGy in 6 to 7 weeks is not feasible for many
patients in a palliative setting. Hypofractionated regimens
are associated with high response rates.4-8 We describe a
case of bulky CTCL of the head treated with a unique
adaptation of the Stanford technique.Case Report
A 76-year-old female presented for consideration of
radiation therapy for CTCL with large cell transformation.
She was diagnosed 4 years prior and treated with light
therapy. The disease transformed into a more active state 3
years after diagnosis and progressed through 5 different
systemic therapies. Findings at consultation included
disfiguring head tumors (Fig 1). The largest lesion
measured 4.0 × 3.0 × 2.0 cm. The lesions were pruritic
and bled easily. Palliative external beam radiation therapy
was recommended.Conflicts of interest: None.
⁎ Corresponding author. Department of Radiation Oncology, Mayo
Clinic, 200 First St SW, Rochester, MN 55905.
E-mail address: martenson.james@mayo.edu (J.A. Martenson).
http://dx.doi.org/10.1016/j.prro.2015.10.021
1879-8500/© 2016 The Authors. Published by Elsevier Inc. on behalf of Ameri
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/Treatment was delivered using an adaptation of the
Stanford 6-field technique with a linear accelerator. The
standard 6-MeV electron beam could not be used because
of the desired treatment depth being several centimeters;
therefore, 12-MeV electrons were used. The 25 × 25 cm2
cone was used to cover the patient’s head and neck, at
extended distance. The patient stood 10 cm behind a
Plexiglas spoiler (91 cm × 91 cm × 0.4 cm) located 140 cm
from the electron source. Eye and mouth shields were not
used. The gantry was rotated to 270°. The projected light
field was used as a guide for centering the patient’s head
and neck during treatments. Lead sheets were secured to
the spoiler to reduce dose inferior to the treatment
area. Six fields were delivered per treatment using
1000 MU/minute dose rate with the patient rotating 60°
clockwise between fields.
The conversion factor to calculate the MU required to
deliver 400 cGy per fraction was determined using a
Markus-type parallel plate ion chamber and an electrometer.
The parallel plate chamber was cross calibrated with an
Accredited Dosimetry Calibration Laboratory–calibrated
Farmer chamber. Initially, a cGy/nanoCoulomb calibration
factor for the 12-MeVbeamwas obtained using a 10×10 cm2
standard cone. The front surface of the ion chamber was
placed at a 2.6-cm depth in solid water at 100 cm source-skin
distance (SSD), and the charge resulting from 100 MU was
recorded. The chamber and phantomwere thenmoved behind
the spoiler to the treatment geometry of 150 cm SSD to thecan Society for Radiation Oncology. This is an open access article under
).
Figure 1 Exophytic lesions present on head and neck at time of radiation oncology consultation.
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from 1000 MU delivery was recorded. These values were
used to calculate the cGy/MU conversion factor for the
treatment geometry.Figure 2 Setup for pretreatment dosimetric verification using a Rand
the location of films placed axially at the level of the eyebrows, nose,The body factor for this beam energy and treatment
conditions was measured using Gafchromic EBT3 film
(Ashland ISP Advanced Materials, Bridgewater, NJ) and a
cylindrical solid water phantom 15 cm long × 25 cm ino phantom and Gafchromic EBT3 film. The dashed lines indicate
and neck.
Figure 3 Results of dosimetric film measurements in the axial plane on the Rando phantom at eyebrow level (A) and in the sagittal
plane (B). The thick, protruding ears caused a dose-shadowing effect responsible for the 380 to 400 cGy isodose lines breaking up
circumferentially in the axial plane.
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of dose delivered to a point on the phantom rotated through
all 6 treatment fields to the dose delivered from a single
anterior field.
Before delivery to the patient, the treatment plan was
verified with dosimetric measurements using GafchromicFigure 4 Complete response 2 mEBT3 film and a Rando anthropomorphic phantom (The
Phantom Laboratory, Salem, NY). The phantom was
placed in treatment position using Styrofoam blocks to
simulate the patient’s height (Fig 2). Gafchromic films
were placed axially within the phantom at the level of the
eyebrows, nose, and neck. The phantom was rotated 60°onths following last treatment.
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SSD) at each position. All film analysis was performed
with FilmQA Pro software (Ashland ISP Advanced
Materials) using a 1-scan protocol9 and triple-channel
dosimetry.10 Fig 3 shows the isodose profile results of the
film measurements.
Slight adjustments (b10%) to monitor units used for
treatment were made based on results of in vivo dosimetry
measurements. These measurements were made by taping
2 × 2 cm2 pieces of Gafchromic film, each wrapped in a
single layer of plastic wrap, onto the patient’s surface. The
plastic wrap was used to keep films clean for scanning and
analysis. Left cheek and neck, right cheek, anterior chin,
and posterior neck locations were monitored.
The patient received 1600 cGy in 4 weekly fractions.
Follow-up 1 week after the last fraction revealed a
near-complete response of all head lesions. Evaluation 2
months later revealed a complete response (Fig 4).At this time,
the patient reported complete alopecia and mild xerostomia.Discussion
CTCL almost always recurs after treatment, especially
in tumor-stage disease. Accordingly, palliative therapy
aimed at controlling lesions and minimizing toxicities is
indicated. Our case demonstrates feasibility of a Stanford
technique adaptationwith reduced radiation dose and fewer
treatment fractions in a patient with extensive head tumors.
The original Stanford technique used multiple fields to
administer ≥3000 cGy over 6 to 7 weeks.1,3 Complete
response rates for tumor-stage disease are lower than rates
for limited plaques: 36% versus 98%.3 The lengthy course
and toxicities associated with higher doses are additional
disadvantages. Thomas et al reported a 94.4% complete
response rate with a single 700 to 800 cGy fraction.6 Of the
34 lesions with tumor morphology, 25 had a complete
response in all treated sites. Similarly, Neelis et al reported
a 92% complete response rate with 800 cGy in 2 fractions.5
A total of 400 cGy once weekly is also an effective
technique, with a 90% complete regression rate.4,8
Alternatives to the traditional standing position are also
effective Stanford adaptations.11The nonstandard nature of our approach required
dosimetric verification before delivery. Placement of
Gafchromic film within the Rando phantom allowed for
visualization of the treatment depth and approximate dose
distribution. However, because of differences between the
phantom and patient geometry, combined with uncer-
tainties resulting from a clinical setup, in vivo dosimetry
should also be performed. Gafchromic film secured
directly on the patient is useful in this regard because it
is nearly tissue-equivalent, exhibits no angular or dose-rate
response, and requires no wires or electronics that may
interfere with patient positioning.References
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